These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33155691)

  • 41. Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy.
    Chien YH; Lee NC; Peng SF; Hwu WL
    Pediatr Res; 2006 Sep; 60(3):349-52. PubMed ID: 16857770
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Muscle MRI Findings in Childhood/Adult Onset Pompe Disease Correlate with Muscle Function.
    Figueroa-Bonaparte S; Segovia S; Llauger J; Belmonte I; Pedrosa I; Alejaldre A; Mayos M; Suárez-Cuartín G; Gallardo E; Illa I; Díaz-Manera J;
    PLoS One; 2016; 11(10):e0163493. PubMed ID: 27711114
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease.
    Moriggi M; Capitanio D; Torretta E; Barbacini P; Bragato C; Sartori P; Moggio M; Maggi L; Mora M; Gelfi C
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799647
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy.
    Pascarella A; Terracciano C; Farina O; Lombardi L; Esposito T; Napolitano F; Franzese G; Panella G; Tuccillo F; la Marca G; Bernardini S; Boffo S; Giordano A; Di Iorio G; Melone MAB; Sampaolo S
    J Cell Physiol; 2018 Aug; 233(8):5829-5837. PubMed ID: 29215735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy.
    Gruhn KM; Heyer CM; Güttsches AK; Rehmann R; Nicolas V; Schmidt-Wilcke T; Tegenthoff M; Vorgerd M; Kley RA
    Mol Genet Metab Rep; 2015 Jun; 3():58-64. PubMed ID: 26937398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.
    Young SP; Piraud M; Goldstein JL; Zhang H; Rehder C; Laforet P; Kishnani PS; Millington DS; Bashir MR; Bali DS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):50-8. PubMed ID: 22252961
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.
    Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS
    Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnosis of Pompe disease: muscle biopsy vs blood-based assays.
    Vissing J; Lukacs Z; Straub V
    JAMA Neurol; 2013 Jul; 70(7):923-7. PubMed ID: 23649721
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autopsy findings in late-onset Pompe disease: a case report and systematic review of the literature.
    Hobson-Webb LD; Proia AD; Thurberg BL; Banugaria S; Prater SN; Kishnani PS
    Mol Genet Metab; 2012 Aug; 106(4):462-9. PubMed ID: 22664150
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
    Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
    Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease].
    Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ
    Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An integrative correlation of myopathology, phenotype and genotype in late onset Pompe disease.
    Kulessa M; Weyer-Menkhoff I; Viergutz L; Kornblum C; Claeys KG; Schneider I; Plöckinger U; Young P; Boentert M; Vielhaber S; Mawrin C; Bergmann M; Weis J; Ziagaki A; Stenzel W; Deschauer M; Nolte D; Hahn A; Schoser B; Schänzer A
    Neuropathol Appl Neurobiol; 2020 Jun; 46(4):359-374. PubMed ID: 31545528
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantitative whole-body magnetic resonance imaging in children with Pompe disease: Clinical tools to evaluate severity of muscle disease.
    Fernandes SA; Khan AA; Boggs T; Bowling M; Austin S; Stefanescu M; Case L; Kishnani PS
    JIMD Rep; 2021 Jan; 57(1):94-101. PubMed ID: 33473345
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Study of the effect of anti-rhGAA antibodies at low and intermediate titers in late onset Pompe patients treated with ERT.
    Fernández-Simón E; Carrasco-Rozas A; Gallardo E; González-Quereda L; Alonso-Pérez J; Belmonte I; Pedrosa-Hernández I; Montiel E; Segovia S; Suárez-Calvet X; Llauger J; Mayos M; Illa I; Barba-Romero MA; Barcena J; Paradas C; Carzorla MR; Creus C; Coll-Cantí J; Díaz M; Domínguez C; Fernández-Torrón R; García-Antelo MJ; Grau JM; López de Munáin A; Martínez-García FA; Morgado Y; Moreno A; Morís G; Muñoz-Blanco MA; Nascimento A; Parajuá-Pozo JL; Querol L; Rojas R; Robledo-Strauss A; Rojas-Marcos Í; Salazar JA; Usón M; Díaz-Manera J
    Mol Genet Metab; 2019; 128(1-2):129-136. PubMed ID: 31378569
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LOPED study: looking for an early diagnosis in a late-onset Pompe disease high-risk population.
    Musumeci O; la Marca G; Spada M; Mondello S; Danesino C; Comi GP; Pegoraro E; Antonini G; Marrosu G; Liguori R; Morandi L; Moggio M; Massa R; Ravaglia S; Di Muzio A; Filosto M; Tonin P; Di Iorio G; Servidei S; Siciliano G; Angelini C; Mongini T; Toscano A;
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):5-11. PubMed ID: 25783438
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sonographic evaluations of the skeletal muscles in patients with Pompe disease.
    Chiu YH; Liao CL; Chien YH; Wu CH; Özçakar L
    Eur J Paediatr Neurol; 2023 Jan; 42():22-27. PubMed ID: 36508847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Alarming signs and symptoms in the early diagnostics of late onset Pompe disease: super omnia clinica].
    Nikitin SS; Kurbatov SA; Bredelev VA; Kovalchuk MO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(12):19-24. PubMed ID: 26978490
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute progression of neuromuscular findings in infantile Pompe disease.
    Burrow TA; Bailey LA; Kinnett DG; Hopkin RJ
    Pediatr Neurol; 2010 Jun; 42(6):455-8. PubMed ID: 20472203
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Infantile-onset Pompe disease: Diagnosis and management.
    Bay LB; Denzler I; Durand C; Eiroa H; Frabasil J; Fainboim A; Maxit C; Schenone A; Spécola N
    Arch Argent Pediatr; 2019 Aug; 117(4):271-278. PubMed ID: 31339275
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Approach to gene therapy of glycogenosis type II (Pompe disease).
    Poenaru L
    Mol Genet Metab; 2000 Jul; 70(3):163-9. PubMed ID: 10924270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.